UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.504

Sortiert nach

Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

Nature communications, 2022-06, Vol.13 (1), p.3246-11, Article 3246

2022

Link zum Volltext

Verfügbarkeit prüfen

Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

Nature communications, 2023-01, Vol.14 (1), p.260-260, Article 260

2023

Link zum Volltext

Verfügbarkeit prüfen

Drug resistance reversal—are we getting closer?

European Journal of Cancer, 2003-11, Vol.39 (17), p.2450-2461

2003

Link zum Volltext

Verfügbarkeit prüfen

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours

European journal of cancer (1990), 2018-11, Vol.103, p.17-23

2018

Link zum Volltext

Verfügbarkeit prüfen

Understanding Oestrogen Receptor Function in Breast Cancer and its Interaction with the Progesterone Receptor. New Preclinical Findings and their Clinical Implications

Clinical oncology (Royal College of Radiologists (Great Britain)), 2016-01, Vol.28 (1), p.1-3

2016

Link zum Volltext

Verfügbarkeit prüfen

An early review of 800 laparoscopic cholecystectomies at a university-affiliated community teaching hospital

The American surgeon, 1992-03, Vol.58 (3), p.206

1992

Link zum Volltext

Verfügbarkeit prüfen

The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials

European journal of gynaecological oncology, 2012, Vol.33 (2), p.211-213

2012

Link zum Volltext

Verfügbarkeit prüfen

A multicentre study of the in-vitro activity of cefotaxime, cefuroxime, ceftazidime, ofloxacin and ciprofloxacin against blood and urinary pathogens

Journal of antimicrobial chemotherapy, 1994-11, Vol.34 (5), p.639-648

1994

Link zum Volltext

Verfügbarkeit prüfen

An institutional review of the management of choledocholithiasis in 1616 patients undergoing laparoscopic cholecystectomy

The American surgeon, 1994-04, Vol.60 (4), p.273

1994

Link zum Volltext

Verfügbarkeit prüfen

Handbook of culture media for food and water microbiology

3rd ed., 2011

Link zum Volltext

Verfügbarkeit prüfen

Hereditary and Sporadic Cancers Respond to Niraparib

Cancer discovery, 2013-08, Vol.3 (8), p.OF8-OF8

2013

Link zum Volltext

Verfügbarkeit prüfen

Basket of baskets (BoB): A modular, open label, phase II, multicenter study to evaluate targeted agents in molecularly selected populations with advanced solid tumors

JOURNAL OF CLINICAL ONCOLOGY, 2019, Vol.37 (15_suppl), p.TPS3151-TPS3151

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT1-01-07: PIONEER- Pre-operative wIndOw study of letrozole plus PR agonist megestrol acetate versus letrozole aloNE in post-menopausal patients with ER-positive breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT1-01-07-OT1-01-07

2019

Link zum Volltext

Verfügbarkeit prüfen

Carotid patch angioplasty: Immediate and long-term results

Journal of vascular surgery, 1990-09, Vol.12 (3), p.326-333

1990

Link zum Volltext

Verfügbarkeit prüfen

Carbon cycling in northern peatlands

1, 2009

Link zum Volltext

Verfügbarkeit prüfen

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: A single-center experience

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.2519-2519

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-14-26: Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including HER2-positive breast cancer patients with brain metastases

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P4-P4-14-26

2016

Link zum Volltext

Verfügbarkeit prüfen

A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.2613-2613

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT1-04-01: Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT1-04-01-OT1-04-01

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT2-01-11: Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT2-01-11-OT2-01-11

2017

Link zum Volltext

Verfügbarkeit prüfen

Utility of novel dynamic clinical indices in patients (pts) enrolled in a phase I (Ph I) oncology trial as markers of prognosis and treatment benefit

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.2555-2555

2011

Link zum Volltext

Verfügbarkeit prüfen

A first-in-human phase I study of JNJ-26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced cancer with evidence of target modulation and antitumor activity

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3024-3024

2011

Link zum Volltext

Verfügbarkeit prüfen

A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3004-3004

2011

Link zum Volltext

Verfügbarkeit prüfen

Final results of a translational phase l study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3001-3001

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 2.504

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.231)
Mit Volltextzugriff
(2.121)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.656)
Life Sciences & Biomedicine
(1.343)
Humans
(954)
Female
(735)
Biological And Medical Sciences
(576)
Male
(477)
Animals
(403)
Medical Sciences
(396)
Adult
(379)
Middle Aged
(272)
Physical Sciences
(255)
Fundamental And Applied Biological Sciences. Psychology
(197)
Aged
(196)
Pregnancy
(180)
Infectious Diseases
(149)
Physics
(140)
Surgery
(136)
Technology
(128)
Adolescent
(119)
Child
(115)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(16)
... seit 30 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

Drug resistance reversal—are we getting closer?

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours

Understanding Oestrogen Receptor Function in Breast Cancer and its Interaction with the Progesterone Receptor. New Preclinical Findings and their Clinical Implications

An early review of 800 laparoscopic cholecystectomies at a university-affiliated community teaching hospital

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials

A multicentre study of the in-vitro activity of cefotaxime, cefuroxime, ceftazidime, ofloxacin and ciprofloxacin against blood and urinary pathogens

An institutional review of the management of choledocholithiasis in 1616 patients undergoing laparoscopic cholecystectomy

Handbook of culture media for food and water microbiology

Hereditary and Sporadic Cancers Respond to Niraparib

Basket of baskets (BoB): A modular, open label, phase II, multicenter study to evaluate targeted agents in molecularly selected populations with advanced solid tumors

Abstract OT1-01-07: PIONEER- Pre-operative wIndOw study of letrozole plus PR agonist megestrol acetate versus letrozole aloNE in post-menopausal patients with ER-positive breast cancer

Carotid patch angioplasty: Immediate and long-term results

Carbon cycling in northern peatlands

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: A single-center experience

Abstract P4-14-26: Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including HER2-positive breast cancer patients with brain metastases

A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941

Abstract OT1-04-01: Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy

Abstract OT2-01-11: Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

Utility of novel dynamic clinical indices in patients (pts) enrolled in a phase I (Ph I) oncology trial as markers of prognosis and treatment benefit

A first-in-human phase I study of JNJ-26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced cancer with evidence of target modulation and antitumor activity

A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors

Final results of a translational phase l study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers

Suchergebnisse filtern